The Phenomix CEO discusses recent data that suggests that patients may not be prepared for the side effects and unexpected costs of GLP-1s. GLP-1 drugs continue to dominate the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results